What type of treatment is primarily indicated for active CNV?

Anti-VEGF therapy is primarily indicated for active choroidal neovascularization (CNV) because it directly targets the underlying mechanism of neovascularization. Active CNV often occurs in conditions such as age-related macular degeneration (AMD), where elevated levels of Vascular Endothelial Growth Factor (VEGF) promote abnormal blood vessel growth beneath the retina. Anti-VEGF agents are designed to inhibit the action of this protein, thereby reducing the development and leakage of these unwanted blood vessels, leading to improved vision outcomes and stabilization of the disease.

This treatment has become a cornerstone in managing active CNV due to its effectiveness in decreasing the severity of vision loss associated with this condition. By inhibiting VEGF, anti-VEGF therapy not only helps in reducing the activity of CNV but also promotes retinal health, making it a preferred choice in clinical practice.